Overview

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).

Phase:

Phase 2

Details

Lead Sponsor:

Amgen
Onyx Therapeutics, Inc.